Mindmaze Therapeutics Holding Sa · SIX:MMTX
Mindmaze Therapeutics Holding Sa — Investor Presentation (October 2025)
35 slides from Mindmaze Therapeutics Holding Sa's investor presentation, October 2025
Slide 1: MindMaze Therapeutics
MindMaze Therapeutics AI-Powered Neurotherapeutics Transforming Brain Health Company Presentation October 2025
Slide 2: Important Notice
Important Notice THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF SWISS FINANCIAL SERVICES ACT (“FINSA”), NOR A PROSPECTUS UNDER ANY OTHER APPLICABLE LAWS AND SHOULD NOT BE TREATED AS OFFERING MATERIALS OF ANY SORT AND IS FOR INFORMATION PURPOSES ONLY. THE INFORMATION CONTAINED H
Slide 3: Contents
Contents 1. Value Proposition 2. Brain Health Pioneer 3. Offering and Market Segments 4. What’s Next 5. Outlook & Transaction Overview page 3
Slide 4: Value Proposition
OORELIEF mindmaze Value Proposition page 4
Slide 5: Business Combination and Listing on SIX
Business Combination and Listing on SIX MindMaze Therapeutics: Shaping the Future of Precision Neurology NXG MindMaze Therapeutics Holding SA1) • Strong foundation for AI-enabled platform bridging software clinical interventions and neurotechnology ‒ Strong Clinical Evidence addressing multiple • In
Slide 6: Overview of RELIEF THERAPEUTICS
Overview of RELIEF THERAPEUTICS Leverage 30 Years of Drug Delivery Expertise Focus & Differentiators • Commercial-stage biopharmaceutical company with a 30-year track record of leveraging patented drug-delivery platforms to develop differentiated products in rare and specialty indications • Headquar
Slide 7: Combined Entity – MindMaze Therapeutics
Combined Entity – MindMaze Therapeutics Creates a Precision Neurology Platform primed for significant value creation and rapid growth • NXG includes assets from legacy MindMaze Group, including its intellectual property • USD 350m invested over last decade to develop 1st of its kind neurotherapeutic
Slide 8: MindMaze Therapeutics Investment Case
MindMaze Therapeutics Investment Case Building the industry’s foremost AI-enabled Precision Neurology Company • Neurological conditions now the leading cause of disability worldwide PROBLEM • Valued at USD 1 trillion, the burden is unsustainable as populations age while resources shrink • Drug and d
Slide 9: End-to-End Neurotherapeutic Platform
End-to-End Neurotherapeutic Platform A Full Suite of Solutions Spanning the Continuum of Care Impairment reducing, Function Function enhancing: Clinical Protocols enhancing: 2-3 weeks, daily 90-120 8-16 weeks, 240 mins per week, Remote Therapist Support, Feedback and mins Time on Task Time on Task M
Slide 10: Validation of Offering and Go-To-Market Success
Validation of Offering and Go-To-Market Success USD 350m invested to scale-up a transformative Brain Health Platform ~300 >25 12 FDA Healthcare Providers - Centers of excellence and national healthcare providers Clinical Patents Clearance/Listings Robotics to AI, & CE Marks Value-based Care (VBC)
Slide 11: Significant Cost Saving
Significant Cost Saving Demonstrating the economic value of our programs Standard 1:1 therapy MindMaze Training USD1,903 per patient USD338 per patient 100% therapist utilization 82% Cost 20% therapist utilization (80% patient self-training) Based on 36 hrs of training Savings Based on 36 hrs of tra
Slide 12: Clinical and Real-World Evidence
Clinical and Real-World Evidence Demonstrating Clinical Value in Core Neurological Conditions 50+ Studies Support commercial portfolio claims and market access Stroke Parkinson’s At-Risk Aging • Demonstrating improvements in upper-limb and hand, gait, balance, fall risk and cognition in core disease
Slide 13: Brain Health Pioneer
2 Brain Health Pioneer page 13
Slide 14: High Burden of Neurological Disease
High Burden of Neurological Disease Large addressable markets with untapped potential Neurological disorders are the leading cause of As populations increase and grow older, the burden will disability and the second leading cause of death only increase … worldwide. [Global Burden of Disease Study –
Slide 15: MindMaze Approach - Rewiring the Brain
MindMaze Approach - "Rewiring the Brain" Purpose-driven platform consolidating Neuroprotection & Neurorestoration Market Injury / Trauma Causes of Pathways Size impairment to Rewiring TODAY TOMORROW (USD) Injury/Trauma Training Neuro-therapeutics/- Expanding into multiple >200bn Induced stress techn
Slide 16: MindMaze Approach - Behavioral Interventions
MindMaze Approach - Behavioral Interventions Building on proven benefits of behavioral interventions Stroke Parkinson’s At-Risk Aging Intensive arm training, especially Exercise leads to dual • Long-term exercise reduces risk of early after insult, leads to improved neuroprotective and Alzheimer
Slide 17: A Comprehensive Brain Health Platform
A Comprehensive Brain Health Platform Uniquely positioned to unlock the massive potential of the neurology market Scale the New Standard of Care in Brain Health Walk the Plan to Tap the Massive Market Potential Expand footprint across market segments from providers/payers to consumer Full-body, move
Slide 18: Growth & Development Milestones
Growth & Development Milestones A decade in the making: Pioneering 1st platform for motor and cognitive disease modification in brain disorders 2023 2019 2017 Launches Launches Izar, first- of- 2025 2013 Holds ISO 13485 MindMaze Labs. its-kind, CE certification. Gains Develops 2024-April 2025 Distri
Slide 19: Clinical and Real-World Evidence
Clinical and Real-World Evidence Raising the bar with strong clinical evidence and a robust late-stage pipeline Study Type Indication Study Design n= Research Institution Feasibility RWE1) RCT2) Stroke SMARTS-II: Enhance motor acute Recovery with intensive training 24 completed Johns Hopkins, Columb
Slide 20: Competitive Landscape
Competitive Landscape MindMaze stands out among HealthTech innovators with a unified platform Relative Positioning (illustrative1) Mid-Sized and Large Markets Brain Computer Interfaces AI-Enabled Integrated Solutions AI enabled Platform OFFEREING PILLARS Software delivered clinical Intervention Work
Slide 21: Offering and Market Segments
3 Offering and Market Segments page 21
Slide 22: End-to-end Precision Neurology Platform
End-to-end Precision Neurology Platform Seamlessly integrated AI-enabled digital therapeutics, neural interfaces and clinical workflow automation AI-Driven Platform Cloud Computing Hardware & Mechanical Design “IMAX Experience” “Netflix Experience” In-clinic/Outpatient Outpatient/Home Computer Visio
Slide 23: Outreach with Precision Neurology Offering
Outreach with Precision Neurology Offering Disease-Modifying Neurotherapeutics, Monitoring & Peripheral Devices delivered across patient journey MindPod Physilog The world’s first immersive Digital assessments for neurobehavioral platform measuring and quantifying gait, balance and cognitive functio
Slide 24: Comprehensive Digital Monitoring Platform
Comprehensive Digital Monitoring Platform In-clinic & home-based assessments and monitoring endpoints for major neurological diseases ● Optimize treatments: comprehensive battery of assessment measures to optimize delivery of MindMaze’s digital neurotherapeutic offering ● Deliver Tele-Rehab: service
Slide 25: Implementation Examples
Implementation Examples Go-To-Market Successes include Partnership with Vibra (US) and SwissNeuroReb (Switzerland & EU) Flagship Project of Innoswiss Clinical Implementation The Swiss Neurorehab project introduces a paradigm shift in neurorehabilitation • Commercial implementation across facilities
Slide 26: Pharma Partnerships – Go-To-Market Strategy
Pharma Partnerships – Go-To-Market Strategy Powering pharma leadership to capture advantage and sustain pricing in the USD100bn+ neurology drug space 1 1 2 3 Next big thing Enable “Around the Pill”/Pill+ strategies Accelerate “Data Play” strategies through the promotion of drugs with our Enable “Bey
Slide 27: What's Next
OORELIEF mindmaze What’s Next page 27
Slide 28: Growth Path – AI Engine
Growth Path – AI Engine AI-powered platform transforms 1.2bn monthly data points into actionable insights Continuum of Care Platform Standalone AI Expansion • Assessments • Remote Monitoring Combinatory AI Expansion • Telehealth Services • Tailored Content & Games Beyond Patient at Tech the Pill Hom
Slide 29: Outlook & Transaction Overview
5 Outlook & Transaction Overview page 29
Slide 30: Growth Potential
Growth Potential Revenue Potential > CHF 200M by FY2031 MindMaze/NXG Relief AI Platform Providers/Payers Pharma Partnerships Commercial Expansion RLF-TD011 (EB) RLF-OD032 (PKU) powered by AI Geography US/Global Global US/Global US + EU3 US + EU3 US: Stroke ~7m/ Tbd, depending on type Est. # of Tbd,
Slide 31: HealthTech Peers
HealthTech Peers Peer Benchmarking demonstrates predominantly robust double-digit Sales Multiples Positioning & Valuation (Sales Multiples¹) of Public and Private Peers Selected Public Company Trading Valuation & Topline Growth Market Sales EV/Sales EV/EBITDA Brain 3) n.a. Company Description Cap2)
Slide 32: Transaction Overview
Transaction Overview Summary NXG Therapeutics Holding SA • In April 2025, NXG acquired substantially all of the • NXG will serve as the interim entity for the Background assets and intellectual property of MindMaze Group contemplated business combination with Relief SA and MindMaze SA • Business com
Slide 33: Transaction Structure
Transaction Structure Business Combination – Contribution of all NXG Shares by incumbent NXG Shareholders into Relief for new Relief Shares ❶ Preparation of Business Combination NXG – Relief NXG, a privately held Swiss HealthTech SH1 SH2 SH3 SH20,000 SH1 SH2 SHn company, is headquartered in Lausan
Slide 34: Transaction Structure
Transaction Structure Post implementation of Business Combination, intention to uplist the combined entity on NASDAQ via ADR III (from OTC ADR I) ❸ Implementation of Business Combination SH1 SH2 New investors Incumbent NXG Shareholders to contribute their NXG SH1 SH2 SH3 SH20,000 SHn Shares into R
Slide 35: Thank You.
To accelerate each human’s ability to learn, recover, and adapt through advanced neuroscience and technology Thank You. 35
MindMaze Therapeutics — Investor Presentation (October 2025) on 6ix